OnKure Therapeutics (OKUR) Net Cash Flow (2020 - 2026)
OnKure Therapeutics' (OKUR) quarterly Net Cash Flow came in at $133.1 million in Q1 2026, up 1043.66% YoY from $11.6 million in Q1 2025, and up 1279.47% on a QoQ basis from -$11.3 million in Q4 2025.
OnKure Therapeutics (OKUR) Net Cash Flow (2020 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 7 years of Net Cash Flow data on file, last reported at $133.1 million in Q1 2026.
- Quarterly Net Cash Flow rose 1043.66% year-over-year to $133.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.4 million (up 23.29% YoY) and the FY2025 annual result came in at -$51.7 million, down 163.93% from the prior year.
- Net Cash Flow improved to $133.1 million in Q1 2026, from -$11.3 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $133.1 million in Q1 2026 to a low of -$56.1 million in Q3 2022.
- A 5-year average of $4.5 million and a median of -$10.6 million in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow slumped 2313.09% — and 2026, when it soared 1043.66%.
- Tracing OKUR's Net Cash Flow over 5 years: stood at -$42.2 million in 2022, then jumped by 162.84% to $26.5 million in 2023, then soared by 287.6% to $102.8 million in 2024, then tumbled by 110.97% to -$11.3 million in 2025, then surged by 1279.47% to $133.1 million in 2026.
- The last three Net Cash Flow figures came in at $133.1 million (Q1 2026), -$11.3 million (Q4 2025), and -$13.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | OnKure Therapeutics | 196.98 Mn | 20.60 Mn | - | -25.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.60 Mn |
| Jun 30, 2026 | -25.60 Mn |
| Mar 31, 2026 | 133.06 Mn |
| Mar 31, 2026 | 133.06 Mn |
| Dec 31, 2025 | -11.28 Mn |
| Dec 31, 2025 | -11.28 Mn |
| Sep 30, 2025 | -13.04 Mn |
| Sep 30, 2025 | -13.04 Mn |
| Jun 30, 2025 | -13.29 Mn |
| Jun 30, 2025 | -13.29 Mn |
| Mar 31, 2025 | -14.10 Mn |
| Mar 31, 2025 | -14.10 Mn |
| Dec 31, 2024 | 102.80 Mn |
| Dec 31, 2024 | 102.80 Mn |
| Sep 30, 2024 | -10.67 Mn |
| Sep 30, 2024 | -10.67 Mn |
| Jun 30, 2024 | -615,000.00 |
| Jun 30, 2024 | -615,000.00 |
| Mar 31, 2024 | -10.63 Mn |
| Mar 31, 2024 | -10.63 Mn |